OnCo

Cutaneous squamous cell carcinoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersFRαRisk group
Early / localised··2
Advanced, first line1··
Third line and beyond·1·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupLocalised low- and high-riskExcision with margin control or Mohs micrographic surgery; adjuvant radiotherapy for high-risk features (perineural invasion, positive margins); nodal evaluation for very high risk.91
Risk groupHigh-risk after surgery and radiotherapyAdjuvant cemiplimab (C-POST, 2025: reduced locoregional and distant recurrence).81

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersLocally advanced or metastaticCemiplimab, pembrolizumab or cosibelimab; neoadjuvant cemiplimab for resectable stage II-IV to shrink surgery (51% pCR).98

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
FRαImmunotherapy-ineligible or refractoryCetuximab ± radiotherapy, platinum-based chemotherapy, capecitabine; trials of intratumoural agents (RP1) and EGFR ADCs.87

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.